Side-by-side comparison of AI visibility scores, market position, and capabilities
Seismic Therapeutic raised $222M+ total ($121M Series B in 2023, $25M in 2025) using its IMPACT ML platform; dosed first patient in Phase 1 for S-4321 bifunctional antibody in autoimmune disease.
Seismic Therapeutic is a clinical-stage biotechnology company based in Boston, Massachusetts that applies machine learning to the discovery and development of novel immunotherapies for autoimmune diseases. Founded with a focus on precision immunology, Seismic built its IMPACT platform to model the complex biology of adaptive immunity — identifying which immune cell populations drive specific autoimmune conditions and designing biologics that precisely modulate those populations without broadly suppressing the immune system. This targeted approach aims to produce safer, more effective treatments for conditions like lupus, rheumatoid arthritis, and inflammatory bowel disease.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.